One of the reasons Pfizer sought to purchase Seagen, as part of a $43 billion deal announced this morning, is that the Seattle-based biotech will be able to withstand the coming headwinds of the Inflation Reduction Act and the Medicare price negotiations that come with it.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,